All In Biotech

Drug Trial Radar · NCT03180034

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study ("Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 27,945 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

27,945

Actual

Start

Nov 29, 2017

Primary completion

Aug 21, 2025

Study completion Aug 1, 2028

Sponsor

Sponsor type
NIH
Collaborators
Bill and Melinda Gates Foundation
First posted
Jun 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 12 years, up to 21 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer. Vaccines that protect against infection with these types of human papillomavirus may reduce the risk of cervical cancer. Both Gardasil-9 and Cervarix protect against HPV 16 and 18, which cause 70% of all cervical cancers. However, HPV vaccination rates are too low, especially in countries with very high rates of cervical cancer. HPV vaccines are expensive-many countries cannot afford them-more than one dose is needed, and giving multiple doses is difficult. Researchers want to find out if one dose prevents HPV infection. If it does, more people might get the vaccine.

Conditions

  • Human Papillomavirus Infection
  • Human Papillomavirus-Related Cervical Carcinoma

Interventions

  • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedBiological

    Given IM

  • Questionnaire AdministrationOther

    Ancillary studies

  • Recombinant Human Papillomavirus Bivalent VaccineBiological

    Given IM

  • Recombinant Human Papillomavirus Nonavalent VaccineBiological

    Given IM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of at least one incident persistent human papillomavirus (HPV)-16 and/or HPV-18 cervical infections, counted cumulatively over the follow-up visitsTime frame: Months 12 to 60
  2. Incident persistent HPV-16 and/or HPV-18 cervical infectionsTime frame: Months 54 and 60
  3. Persistent HPV-16 and/or HPV-18 cervical infections (End-of-Study Survey Cohort)Time frame: Baseline, and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

    Liberia, Guanacaste Province, Costa Rica

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.